MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
Monika E HegiEls GenbruggeThierry GorliaRoger StuppMark R GilbertOlivier Louis ChinotLouis Burt NaborsGreg JonesWim Van CriekingeJosef StraubMichael WellerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Low MGMT methylation (gray zone) may confer some sensitivity to temozolomide treatment, hence the lower safety margin should be considered for selecting patients with unmethylated GBM into trials omitting temozolomide.